ASRT vs SRTS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ASRT's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and inconsistent earnings performance. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given negative earnings and high revenue volatility. Despite strong revenue growth (69.4% YoY) and a low price-to-sales ratio (0.54), the company trades at a significant discount due to deep operational losses and poor capital efficiency. Insider selling activity and a 5-year price decline of 80.4% further undermine confidence. The stock's current valuation appears unsustainable without a clear path to sustained profitability.
SRTS exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic YoY revenue decline of 62.20%. While the company maintains a strong liquidity position with a Current Ratio of 9.72 and negligible debt, these are offset by negative operating margins (-63.74%) and a consistent failure to meet earnings estimates. The recent short-term price appreciation contradicts the underlying financial decay and the bearish technical trend score of 0/100. Overall, the company is in a state of operational distress despite its clean balance sheet.
Compare Another Pair
Related Comparisons
ASRT vs SRTS: Head-to-Head Comparison
This page compares Assertio Holdings, Inc. (ASRT) and Sensus Healthcare, Inc. (SRTS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.